M&A Deal Summary

Boston Therapeutics Acquires CureDM

On February 13, 2018, Boston Therapeutics acquired life science company CureDM

Acquisition Highlights
  • This is Boston Therapeutics’ 1st transaction in the Life Science sector.
  • This is Boston Therapeutics’ 1st transaction in the United States.
  • This is Boston Therapeutics’ 1st transaction in Delaware.

M&A Deal Summary
Date 2018-02-13
Target CureDM
Sector Life Science
Buyer(s) Boston Therapeutics
Deal Type Add-on Acquisition

Target

CureDM

Wilmington, Delaware, United States
CureDM, Inc. is a clinical development of the novel peptide therapeutic, HIP2B, for the treatment of type 1 and type 2 diabetes. CureDM is based in Wilmington, Delaware.

Search 201,157 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Boston Therapeutics

Lawrence, Massachusetts, United States
Category Company
Sector Life Science
Revenue 99M USD (2015)
DESCRIPTION

Boston Therapeutics, Inc. is a designer, developer and commercialization of compounds, such as investigational BTI-320, to treat diabetes and diabetes related complications. Boston Therapeutics is based in Lawrence, Massachusetts.

DEAL STATS #
Overall 1 of 1
Sector (Life Science) 1 of 1
Type (Add-on Acquisition) 1 of 1
State (Delaware) 1 of 1
Country (United States) 1 of 1
Year (2018) 1 of 1
Mergr

Product

Company

Legal